Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BT 001

Next Previous
Drug Profile

BT 001

Alternative Names: Antibody-encoding oncolytic virus - BioInvent International/Transgene; BT-001; TG-6030; TG-6030 - Bioinvent International/Transgene; VV-α-CTLA-4

Latest Information Update: 09 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioInvent International; Transgene
  • Class Antibodies; Antineoplastics; Cytokines; Gene therapies; Immunotherapies; Monoclonal antibodies; Oncolytic viruses
  • Mechanism of Action Cell death stimulants; Cytotoxic T-lymphocyte antigen 4 inhibitors; Granulocyte-macrophage colony-stimulating factor expression stimulants; Immunologic cytotoxicity; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 21 Nov 2025 Transgene terminates phase I/II trial in Solid tumours (Monotherapy, Combination therapy, Metastatic disease, Second-line therapy or greater, Late-stage disease) in France, Belgium (Intratumoural) due to sponsor decision following completion of phase I part not driven by safety reason (EudraCT2020-000505-80) (NCT04725331)
  • 20 Oct 2025 Updated efficacy and adverse events data from a phase I/II trial in Solid tumors released by BioInvent and Transgene
  • 17 Oct 2025 Efficacy and adverse events data from a phase I/II trial in Solid tumours presented at the 50th European Society for Medical Oncology Congress, 2025 (ESMO-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top